Financings in Brief: Safeskin
This article was originally published in The Gray Sheet
Executive SummarySafeskin: Files registration statement with SEC for a secondary offering of 3.2 mil. shares by insider shareholders. Neil Braverman, Safeskin's co-chairman and director, will sell 2 mil. shares; 1 mil. shares are slated to be sold by chairman emeritus Irving Jaffe; and 200,000 shares are offered by Chairman, President and CEO Richard Jaffe. Following the offering, Braverman, Jaffe and Jaffe will continue to own approximately 19.4% of Safeskin's voting stock, the company says. Smith Barney and Merrill Lynch are underwriters. Separately, Safeskin adopts a shareholder rights plan that would go into effect if a person or group acquired beneficial ownership of 15% of Safeskin outstanding stock...
You may also be interested in...
As the coronavirus continues to spread, one of the big four global vaccines companies has committed itself to the fight.
Sweden’s mid-sized pharmaceutical company, Swedish Orphan Biovitrum, has expanded into hematology and strengthened its immunology business, growing its top and bottom lines in 2019.
An AAM-sponsored study by researcher Avalere Health has concluded that Medicare Part D policy changes have led to generics being placed on non-generic tiers 53% of the time in 2020, with generics placed on the ‘preferred generic’ Tier 1 just 10% of the time.